From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
Vaccines,
Год журнала:
2024,
Номер
12(5), С. 459 - 459
Опубликована: Апрель 25, 2024
Understanding
the
antibody
response
to
SARS-CoV-2,
virus
responsible
for
COVID-19,
is
crucial
comprehending
disease
progression
and
significance
of
vaccine
therapeutic
development.
The
emergence
highly
contagious
variants
poses
a
significant
challenge
humoral
immunity,
underscoring
necessity
grasping
intricacies
specific
antibodies.
This
review
emphasizes
pivotal
role
antibodies
in
shaping
immune
responses
their
implications
diagnosing,
preventing,
treating
SARS-CoV-2
infection.
It
delves
into
kinetics
characteristics
explores
current
antibody-based
diagnostics,
discussing
strengths,
clinical
utility,
limitations.
Furthermore,
we
underscore
potential
SARS-CoV-2-specific
antibodies,
various
therapies
such
as
monoclonal
polyclonal
anti-cytokines,
convalescent
plasma,
hyperimmunoglobulin-based
therapies.
Moreover,
offer
insights
vaccines,
emphasizing
neutralizing
order
confer
immunity
along
with
emerging
concern
(VOCs)
circulating
Omicron
subvariants.
We
also
highlight
challenges
field,
risks
antibody-dependent
enhancement
(ADE)
shed
light
on
associated
original
antigenic
sin
(OAS)
effect
long
COVID.
Overall,
this
intends
provide
valuable
insights,
which
are
advancing
sensitive
diagnostic
tools,
identifying
efficient
therapeutics,
developing
effective
vaccines
combat
evolving
threat
global
scale.
Язык: Английский
Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants
Viruses,
Год журнала:
2025,
Номер
17(5), С. 691 - 691
Опубликована: Май 10, 2025
Since
its
emergence
in
late
2019,
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
has
continuously
evolved,
giving
rise
to
multiple
variants
that
have
significantly
altered
the
trajectory
of
COVID-19
pandemic.
These
resulted
waves
pandemic,
exhibiting
characteristic
mutations
spike
(S)
protein
may
affected
receptor
interaction,
tissue
tropism,
and
cell
entry
mechanisms.
While
virus
was
shown
primarily
utilize
angiotensin-converting
enzyme
(ACE2)
host
proteases
such
as
transmembrane
serine
protease
(TMPRSS2)
for
into
cells,
alterations
S
changes
binding
affinity
use
alternative
receptors,
potentially
expanding
virus's
ability
infect
different
types
or
tissues,
contributing
shifts
clinical
presentation.
been
linked
variations
disease
severity,
new
manifestations,
transmission
dynamics.
In
this
paper,
we
overview
evolving
utilization
strategies
SARS-CoV-2,
focusing
on
how
influenced
viral
mechanisms
outcomes
across
ongoing
pandemic
waves.
Язык: Английский
Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan
Journal of Infection and Chemotherapy,
Год журнала:
2024,
Номер
31(1), С. 102467 - 102467
Опубликована: Июль 9, 2024
Язык: Английский
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
Human Vaccines & Immunotherapeutics,
Год журнала:
2024,
Номер
20(1)
Опубликована: Ноя. 22, 2024
We
evaluated
the
immunogenicity
of
300
mg
Tixagevimab-Cilgavimab
in
immunocompromised
children
and
adolescents
who
weighed
20
to
>40
kg.
Six
18-year-old
participants
were
divided
into
two
groups
by
body
weight
received
(20
<40
kg)
600
(≥40
Tixagevimab-Cilgavimab,
respectively.
Anti-SARS-CoV-2
receptor-binding
domain
IgG
concentrations
pseudovirus
neutralizing
antibody
(NAb)
titers
measured
at
4,
12,
24
weeks
after
administration
compared
with
reference
data
from
healthy
Thai
2
three
BNT162b2
vaccinations.
Of
59
participants,
49.2%
female,
a
median
(IQR)
age
12
(9,
15)
years;
16
(27.1%)
had
cancer.
NAb
(95%
CI)
for
ancestral
Wuhan
strain
comparatively
high
both
dosing
regimens
(16363.2
[13765.9,
19450.5]
vs
17768.3
[15539.5,
20316.9]
kg
≥40
respectively)
significantly
higher
than
(P
<
0.001
both).
Omicron
BA.4/5
on
par
regimens.
Adverse
events
mild,
well
tolerated,
slightly
more
prevalent
full-dose
Tixagevimab-Cilgavimab.
Minimal
waning
anti-RBD
concentrations,
comparable
reference,
was
observed
concluded
that
half-dose
generated
equivalent
antibodies
standard
doses
three-dose
vaccination.
Further
study
monoclonal
long-acting
larger
cohorts
<6-year-old
are
warranted.
Язык: Английский